Phase 2 Study to Evaluate the Safety of and the Immunogenicity to an Adjuvanted A(H1N1) Influenza Vaccine in HIV-Infected Adults.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2015
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Acronyms VIP-H1N1
- 07 Jun 2017 Biomarkers information updated
- 23 Mar 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 23 Mar 2012 Planned end date changed from 1 Apr 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.